Kritika Singh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kritika Singh has a total of 206 co-authors. Here are the top co-authors by number of shared publications:
- Lea Karatheodoris Davis
Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, USA
9 shared publications - Frank R. Wendt
University of Toronto
3 shared publications - Joel Gelernter
Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA
3 shared publications - Jordan Wassertheil Smoller
Harvard Medical School
3 shared publications - Murray B. Stein
VA San Diego Healthcare System, San Diego, CA, USA
3 shared publications - Daniel F. Levey
Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA
2 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by Springer Nature in Nature Communications
Systematic comparison of affinity plasma proteomic technologies across multiple cohorts reveals generalizability of proteomic prediction
- 8 October 2026
- Published by Springer Nature in Nature Communications
Open AccessSystematic comparison of affinity plasma proteomic technologies across multiple cohorts reveals generalizability of proteomic prediction
- Open Access
Antidepressants are associated with decreased white blood cell counts beyond the effect of statins in individuals with co-morbid depression and coronary artery disease: A longitudinal analysis in the Vanderbilt University Medical Center and All of Us cohorts
Depression and coronary artery disease (CAD) are comorbid, prevalent conditions responsible for significant morbidity and mortality. Understanding the co-occurrence of these conditions can facilitate early diagnosis and treatment recommendations. Routinely prescribed treatments are available for both CAD and depression, and interactions between serotonin signaling, the immune system, and cardiovascular system suggest cross-treatment of CAD and depression may be indicated. In this study we use repeated, longitudinal WBC count measures from over one million participants in the Vanderbilt University Medical Center (VUMC) electronic health records (EHR) to characterize changes in systemic inflammation in response to CAD and depression diagnoses and their respective treatments. After controlling for potential confounders, individuals with comorbid depression-CAD have higher median WBC counts than controls and individuals with depression only but not higher than individuals with CAD only. In our longitudinal modeling cohort of individuals with both depression and CAD, there was a significant decrease in WBC count after statin initiation and after anti-depressant initiation. Additionally, initiating antidepressants after statins was associated with a further decrease in WBC count, however the reverse was not true. This work highlights the continued importance and necessity of evaluating the immunomodulatory effects of depression and CAD and their respective treatments in individuals with both depression and CAD.
Open AccessAntidepressants are associated with decreased white blood cell counts beyond the effect of statins in individuals with co-morbid depression and coronary artery disease: A longitudinal analysis in the Vanderbilt University Medical Center and All of Us cohorts
Depression and coronary artery disease (CAD) are comorbid, prevalent conditions responsible for significant morbidity and mortality. Understanding the co-occurrence of these conditions can facilitate early diagnosis and treatment recommendations. Routinely prescribed treatments are available for both CAD and depression, and interactions between serotonin signaling, the immune system, and cardiovascular system suggest cross-treatment of CAD and depression may be indicated. In this study we use repeated, longitudinal WBC count measures from over one million participants in the Vanderbilt University Medical Center (VUMC) electronic health records (EHR) to characterize changes in systemic inflammation in response to CAD and depression diagnoses and their respective treatments. After controlling for potential confounders, individuals with comorbid depression-CAD have higher median WBC counts than controls and individuals with depression only but not higher than individuals with CAD only. In our longitudinal modeling cohort of individuals with both depression and CAD, there was a significant decrease in WBC count after statin initiation and after anti-depressant initiation. Additionally, initiating antidepressants after statins was associated with a further decrease in WBC count, however the reverse was not true. This work highlights the continued importance and necessity of evaluating the immunomodulatory effects of depression and CAD and their respective treatments in individuals with both depression and CAD.
- Open Access
Genome-wide association study of major anxiety disorders in 122,341 European-ancestry cases identifies 58 loci and highlights GABAergic signaling
The major anxiety disorders (ANX; including generalized anxiety disorder, panic disorder, and phobias ) are highly prevalent, often onset early, persist throughout life, and cause substantial global disability. Although distinct in their clinical presentations, they likely represent differential expressions of a dysregulated threat-response system. Here we present a genome-wide association meta-analysis comprising 122,341 European ancestry ANX cases and 729,881 controls. We identified 58 independent genome-wide significant ANX risk variants and 66 genes with robust biological support. In an independent sample of 1,175,012 self-report ANX cases and 1,956,379 controls, 51 of the 58 associated variants were replicated. As predicted by twin studies, we found substantial genetic correlation between ANX and depression, neuroticism, and other internalizing phenotypes. Follow-up analyses demonstrated enrichment in all major brain regions and highlighted GABAergic signaling as one potential mechanism underlying ANX genetic risk. These results advance our understanding of the genetic architecture of ANX and prioritize genes for functional follow-up studies.
Open AccessGenome-wide association study of major anxiety disorders in 122,341 European-ancestry cases identifies 58 loci and highlights GABAergic signaling
The major anxiety disorders (ANX; including generalized anxiety disorder, panic disorder, and phobias ) are highly prevalent, often onset early, persist throughout life, and cause substantial global disability. Although distinct in their clinical presentations, they likely represent differential expressions of a dysregulated threat-response system. Here we present a genome-wide association meta-analysis comprising 122,341 European ancestry ANX cases and 729,881 controls. We identified 58 independent genome-wide significant ANX risk variants and 66 genes with robust biological support. In an independent sample of 1,175,012 self-report ANX cases and 1,956,379 controls, 51 of the 58 associated variants were replicated. As predicted by twin studies, we found substantial genetic correlation between ANX and depression, neuroticism, and other internalizing phenotypes. Follow-up analyses demonstrated enrichment in all major brain regions and highlighted GABAergic signaling as one potential mechanism underlying ANX genetic risk. These results advance our understanding of the genetic architecture of ANX and prioritize genes for functional follow-up studies.
- 5 April 2024
- Published by Springer Nature in Nature Mental Health
- Vol. 2 (5) , 574-582
Genes associated with depression and coronary artery disease are enriched for cardiomyopathy and inflammatory phenotypes
- 5 April 2024
- Published by Springer Nature in Nature Mental Health
- Vol. 2 (5) , 574-582
Genes associated with depression and coronary artery disease are enriched for cardiomyopathy and inflammatory phenotypes
- Open Access
- 2 February 2024
- Published by Springer Nature in Translational Psychiatry
- Vol. 14 (1) , 1-9
Effects of sex and gender on the etiologies and presentation of select internalizing psychopathologies
The internalizing spectrum encompasses a subset of psychopathologies characterized by emotional liability, anhedonia, anxiousness, distress, and fear, and includes, among others, diagnoses of major depressive disorder (MDD), generalized anxiety disorder (GAD), and posttraumatic stress disorder (PTSD). In this review, we describe the vast body of work highlighting a role for sex and gender in the environment, symptom onset, genetic liability, and disorder progression and comorbidities of MDD, GAD, and PTSD. We also point the reader to different language used in diverse fields to describe sexual and gender minorities that may complicate the interpretation of emerging literature from the social sciences, psychiatric and psychological sciences, and genetics. Finally, we identify several gaps in knowledge that we hope serve as launch-points for expanding the scope of psychiatric studies beyond binarized sex-stratification. Despite being under-represented in genomics studies, placing emphasis on inclusion of sexual and gender diverse participants in these works will hopefully improve our understanding of disorder etiology using genetics as one tool to inform how biology (e.g., hormone concentration) and environmental variables (e.g., exposure to traumatic events) contribute to differences in symptom onset, pattern, and long-term trajectory.
- 2 February 2024
- Published by Springer Nature in Translational Psychiatry
- Vol. 14 (1) , 1-9
Open AccessEffects of sex and gender on the etiologies and presentation of select internalizing psychopathologies
The internalizing spectrum encompasses a subset of psychopathologies characterized by emotional liability, anhedonia, anxiousness, distress, and fear, and includes, among others, diagnoses of major depressive disorder (MDD), generalized anxiety disorder (GAD), and posttraumatic stress disorder (PTSD). In this review, we describe the vast body of work highlighting a role for sex and gender in the environment, symptom onset, genetic liability, and disorder progression and comorbidities of MDD, GAD, and PTSD. We also point the reader to different language used in diverse fields to describe sexual and gender minorities that may complicate the interpretation of emerging literature from the social sciences, psychiatric and psychological sciences, and genetics. Finally, we identify several gaps in knowledge that we hope serve as launch-points for expanding the scope of psychiatric studies beyond binarized sex-stratification. Despite being under-represented in genomics studies, placing emphasis on inclusion of sexual and gender diverse participants in these works will hopefully improve our understanding of disorder etiology using genetics as one tool to inform how biology (e.g., hormone concentration) and environmental variables (e.g., exposure to traumatic events) contribute to differences in symptom onset, pattern, and long-term trajectory.
- Open Access
- 29 November 2023
- Published by Medip Academy in International Journal of Research in Medical Sciences
- Vol. 11 (12) , 4607-4614
Pervasiveness of metabolic syndrome and cardiovascular disease in tribal/rural population of India: a review
Diseases classified as non-communicable diseases (NCDs) are those that are often caused by unhealthy behaviors rather than by infection or by contact with others. One of the main NCDs causing many fatalities is cardiovascular disease (CVD). Recent research has shown that the prevalence of metabolic syndrome (Mets) associated CVDs among tribal populations is increasing in rapid pace. In this review, we have included studies investigating the components of Mets and the relationships between Mets and CVDs. From the assessment of studies, we may predict a significant association between Mets and CVDs as a whole. Our evaluation of these studies revealed that carrying at least three Mets risk components, like hyperglycemia, obesity, dyslipidemia, and high blood pressure, significantly enhances the risk of CVDs. Undernutrition, smoking, and a low intake of fruits and vegetables in the Indian tribal population are the main risk factors for managing Mets associated CVDs. Furthermore, various studies have also shown that Mets may be influenced by genetic and environmental factors. Finally, healthy habits such as a balanced diet and frequent exercise should be introduced from a young age in individuals, to prevent Mets progression. In order to combat the Mets associated CVDs, functionally upgraded primary health centers and special IECs (Information, education and communication) programs may play a beneficial role. Furthermore, strengthening public healthcare systems and focusing on prevention, early identification, and treatment using medical and social interventions can be of immense help in managing the metabolic risk factors that can lead to CVDs.
- 29 November 2023
- Published by Medip Academy in International Journal of Research in Medical Sciences
- Vol. 11 (12) , 4607-4614
Open AccessPervasiveness of metabolic syndrome and cardiovascular disease in tribal/rural population of India: a review
Diseases classified as non-communicable diseases (NCDs) are those that are often caused by unhealthy behaviors rather than by infection or by contact with others. One of the main NCDs causing many fatalities is cardiovascular disease (CVD). Recent research has shown that the prevalence of metabolic syndrome (Mets) associated CVDs among tribal populations is increasing in rapid pace. In this review, we have included studies investigating the components of Mets and the relationships between Mets and CVDs. From the assessment of studies, we may predict a significant association between Mets and CVDs as a whole. Our evaluation of these studies revealed that carrying at least three Mets risk components, like hyperglycemia, obesity, dyslipidemia, and high blood pressure, significantly enhances the risk of CVDs. Undernutrition, smoking, and a low intake of fruits and vegetables in the Indian tribal population are the main risk factors for managing Mets associated CVDs. Furthermore, various studies have also shown that Mets may be influenced by genetic and environmental factors. Finally, healthy habits such as a balanced diet and frequent exercise should be introduced from a young age in individuals, to prevent Mets progression. In order to combat the Mets associated CVDs, functionally upgraded primary health centers and special IECs (Information, education and communication) programs may play a beneficial role. Furthermore, strengthening public healthcare systems and focusing on prevention, early identification, and treatment using medical and social interventions can be of immense help in managing the metabolic risk factors that can lead to CVDs.
- Open Access
T-SEM of 11 Major Psychiatric Disorders: Identification of Gene Expression Patterns for Cross-Disorder Risk and Drug Repurposing
Importance Psychiatric disorders display high levels of comorbidity and genetic overlap, necessitating multivariate approaches for parsing convergent and divergent psychiatric risk pathways. Identifying gene expression patterns underlying cross-disorder risk also stands to propel drug discovery and repurposing in the face of rising levels of polypharmacy. Objective To identify gene expression patterns underlying genetic convergence and divergence across psychiatric disorders along with existing pharmacological interventions that target these genes. Design This genomic study applied a multivariate transcriptomic method, Transcriptome-wide Structural Equation Modeling (T-SEM), to investigate gene expression patterns associated with four genomic factors indexing shared risk across 11 major psychiatric disorders. Follow-up tests, including overlap with gene sets for other outcomes and phenome-wide association studies, were conducted to better characterize T-SEM results. Public databases describing drug-gene pairs were used to identify drugs that could be repurposed to target genes found to be associated with cross-disorder risk. Main Outcomes and Measures Gene expression patterns associated with genomic factors or disorder-specific risk and existing drugs that target these genes. Results In total, T-SEM identified 451 genes whose expression was associated with the genomic factors and 41 genes with disorder-specific effects. We find the most hits for a Thought Disorders factor defined by bipolar disorder and schizophrenia. We identify 39 existing pharmacological interventions that could be repurposed to target gene expression hits for this same factor. Conclusions and Relevance The findings from this study shed light on patterns of gene expression associated with genetic overlap and uniqueness across psychiatric disorders. Future versions of the multivariate drug repurposing framework outlined here have the potential to identify novel pharmacological interventions for increasingly common, comorbid psychiatric presentations.
Open AccessT-SEM of 11 Major Psychiatric Disorders: Identification of Gene Expression Patterns for Cross-Disorder Risk and Drug Repurposing
Importance Psychiatric disorders display high levels of comorbidity and genetic overlap, necessitating multivariate approaches for parsing convergent and divergent psychiatric risk pathways. Identifying gene expression patterns underlying cross-disorder risk also stands to propel drug discovery and repurposing in the face of rising levels of polypharmacy. Objective To identify gene expression patterns underlying genetic convergence and divergence across psychiatric disorders along with existing pharmacological interventions that target these genes. Design This genomic study applied a multivariate transcriptomic method, Transcriptome-wide Structural Equation Modeling (T-SEM), to investigate gene expression patterns associated with four genomic factors indexing shared risk across 11 major psychiatric disorders. Follow-up tests, including overlap with gene sets for other outcomes and phenome-wide association studies, were conducted to better characterize T-SEM results. Public databases describing drug-gene pairs were used to identify drugs that could be repurposed to target genes found to be associated with cross-disorder risk. Main Outcomes and Measures Gene expression patterns associated with genomic factors or disorder-specific risk and existing drugs that target these genes. Results In total, T-SEM identified 451 genes whose expression was associated with the genomic factors and 41 genes with disorder-specific effects. We find the most hits for a Thought Disorders factor defined by bipolar disorder and schizophrenia. We identify 39 existing pharmacological interventions that could be repurposed to target gene expression hits for this same factor. Conclusions and Relevance The findings from this study shed light on patterns of gene expression associated with genetic overlap and uniqueness across psychiatric disorders. Future versions of the multivariate drug repurposing framework outlined here have the potential to identify novel pharmacological interventions for increasingly common, comorbid psychiatric presentations.
- Open Access
Genes associated with depression and coronary artery disease are enriched for inflammation and cardiomyopathy-associated pathways
Background: Depression and Coronary Artery Disease (CAD) are highly comorbid conditions. Approximately 40% of individuals who have one diagnosis will also develop the other within their lifetime. Prior research indicates that polygenic risk for depression increases the odds of developing CAD even in the absence of clinical depression. However, the specific genes and pathways involved in comorbid depression-CAD remain unknown. Results: We identified genes that are significantly associated with both depression and CAD, and are enriched for pathways involved in inflammation and for previous association with cardiomyopathy. We observed increased rate of prevalent, but not incident, cardiomyopathy cases in individuals with comorbid depression-CAD compared to those with CAD alone in three electronic large health record (EHR) datasets. Conclusions: The results of our study implicate genetically regulated inflammatory mechanisms in depression-CAD. Our results also raise the hypothesis that depression-associated CAD may be enriched for cardiomyopathy. Clinical Perspective: What’s New? Gene associations shared between depression and CAD are enriched for prior association with cardiomyopathy phenotypes. Cardiomyopathy is significantly more prevalent in individuals with comorbid depression-CAD than in CAD or depression alone. What are the Clinical Implications? Our work suggests that individuals with comorbid depression-CAD may benefit from screening for cardiomyopathy.
Open AccessGenes associated with depression and coronary artery disease are enriched for inflammation and cardiomyopathy-associated pathways
Background: Depression and Coronary Artery Disease (CAD) are highly comorbid conditions. Approximately 40% of individuals who have one diagnosis will also develop the other within their lifetime. Prior research indicates that polygenic risk for depression increases the odds of developing CAD even in the absence of clinical depression. However, the specific genes and pathways involved in comorbid depression-CAD remain unknown. Results: We identified genes that are significantly associated with both depression and CAD, and are enriched for pathways involved in inflammation and for previous association with cardiomyopathy. We observed increased rate of prevalent, but not incident, cardiomyopathy cases in individuals with comorbid depression-CAD compared to those with CAD alone in three electronic large health record (EHR) datasets. Conclusions: The results of our study implicate genetically regulated inflammatory mechanisms in depression-CAD. Our results also raise the hypothesis that depression-associated CAD may be enriched for cardiomyopathy. Clinical Perspective: What’s New? Gene associations shared between depression and CAD are enriched for prior association with cardiomyopathy phenotypes. Cardiomyopathy is significantly more prevalent in individuals with comorbid depression-CAD than in CAD or depression alone. What are the Clinical Implications? Our work suggests that individuals with comorbid depression-CAD may benefit from screening for cardiomyopathy.
- Open Access
Sex-Specific Association Between Genetic Risk of Psychiatric Disorders and Cardiovascular Diseases
Background: The lack of research on female-specific risk factors for cardiovascular diseases (CVD) has led to sex-based disparities in cardiovascular health. Though epidemiological studies show increased CVD risks amongst individuals with psychiatric disorders, findings on sex differences in comorbidity have been inconsistent. Methods: This genetic epidemiology study examined the sex-specific association between the genetic risk of three psychiatric disorders [major depression (MD), schizophrenia and bipolar disorder], estimated using polygenic scores (PGS), and risks of three CVDs [atrial fibrillation (AF), coronary artery disease (CAD) and heart failure (HF)] in 345,169 European-ancestry individuals (UK Biobank), with analyses replicated in an independent BioVU cohort (N=49,057). Mediation analysis was conducted to determine whether traditional CVD risk factors could explain any observed sex difference. Results: In UK Biobank, PGS MD was significantly associated with the incident risks of all three CVDs in females after multiple testing correction [hazard ratio (HR) AF-female =1.04 (95% CI: 1.02-1.06; p=0.00015); HR CAD-female =1.07 (1.04-1.11; p=2.6E-06); HR HF-female =1.09 (1.06-1.13; p=9.7E-10)], but not in males. These female-specific associations remained even in the absence of any psychiatric disorder diagnosis or psychiatric medication use. Although mediation analysis demonstrated that the association between PGS MD and CVDs in females was partly mediated by baseline BMI, hypercholesterolemia, hypertension and smoking, these risk factors did not explain the higher risk compared to males. The association between PGS MD and CAD was consistent between females who were pre-menopausal and post-menopausal at baseline (mean baseline age of 44.9 and 60.8 years, respectively), while the association with AF and HF was only observed in the baseline post-menopausal cohort. No significant association with CVD risks was observed for the PGS of schizophrenia or bipolar disorder. The positive association of PGS MD with CAD and HF risk in females was replicated in BioVU, where the corresponding associations in males also reached nominal significance. Conclusions: Genetic predisposition to MD confers a greater risk of CVDs in females versus males, even in the absence of any depression diagnosis. This study warrants further investigation into whether genetic predisposition to depression could be useful for improving cardiovascular risk prediction even in the absence of a depression diagnosis, especially in women.
Open AccessSex-Specific Association Between Genetic Risk of Psychiatric Disorders and Cardiovascular Diseases
Background: The lack of research on female-specific risk factors for cardiovascular diseases (CVD) has led to sex-based disparities in cardiovascular health. Though epidemiological studies show increased CVD risks amongst individuals with psychiatric disorders, findings on sex differences in comorbidity have been inconsistent. Methods: This genetic epidemiology study examined the sex-specific association between the genetic risk of three psychiatric disorders [major depression (MD), schizophrenia and bipolar disorder], estimated using polygenic scores (PGS), and risks of three CVDs [atrial fibrillation (AF), coronary artery disease (CAD) and heart failure (HF)] in 345,169 European-ancestry individuals (UK Biobank), with analyses replicated in an independent BioVU cohort (N=49,057). Mediation analysis was conducted to determine whether traditional CVD risk factors could explain any observed sex difference. Results: In UK Biobank, PGS MD was significantly associated with the incident risks of all three CVDs in females after multiple testing correction [hazard ratio (HR) AF-female =1.04 (95% CI: 1.02-1.06; p=0.00015); HR CAD-female =1.07 (1.04-1.11; p=2.6E-06); HR HF-female =1.09 (1.06-1.13; p=9.7E-10)], but not in males. These female-specific associations remained even in the absence of any psychiatric disorder diagnosis or psychiatric medication use. Although mediation analysis demonstrated that the association between PGS MD and CVDs in females was partly mediated by baseline BMI, hypercholesterolemia, hypertension and smoking, these risk factors did not explain the higher risk compared to males. The association between PGS MD and CAD was consistent between females who were pre-menopausal and post-menopausal at baseline (mean baseline age of 44.9 and 60.8 years, respectively), while the association with AF and HF was only observed in the baseline post-menopausal cohort. No significant association with CVD risks was observed for the PGS of schizophrenia or bipolar disorder. The positive association of PGS MD with CAD and HF risk in females was replicated in BioVU, where the corresponding associations in males also reached nominal significance. Conclusions: Genetic predisposition to MD confers a greater risk of CVDs in females versus males, even in the absence of any depression diagnosis. This study warrants further investigation into whether genetic predisposition to depression could be useful for improving cardiovascular risk prediction even in the absence of a depression diagnosis, especially in women.
- 3 March 2022
- Published by Springer Nature in Molecular Psychiatry
- Vol. 27 (3) , 1394-1404
Genetically regulated multi-omics study for symptom clusters of posttraumatic stress disorder highlights pleiotropy with hematologic and cardio-metabolic traits
Posttraumatic stress disorder (PTSD) is a psychiatric disorder that may arise in response to severe traumatic event and is diagnosed based on three main symptom clusters (reexperiencing, avoidance, and hyperarousal) per the Diagnostic Manual of Mental Disorders (version DSM-IV-TR). In this study, we characterized the biological heterogeneity of PTSD symptom clusters by performing a multi-omics investigation integrating genetically regulated gene, splicing, and protein expression in dorsolateral prefrontal cortex tissue within a sample of US veterans enrolled in the Million Veteran Program (N total = 186,689). We identified 30 genes in 19 regions across the three PTSD symptom clusters. We found nine genes to have cell-type specific expression, and over-representation of miRNA-families – miR-148, 30, and 8. Gene-drug target prioritization approach highlighted cyclooxygenase and acetylcholine compounds. Next, we tested molecular-profile based phenome-wide impact of identified genes with respect to 1678 phenotypes derived from the Electronic Health Records of the Vanderbilt University biorepository (N = 70,439). Lastly, we tested for local genetic correlation across PTSD symptom clusters which highlighted metabolic (e.g., obesity, diabetes, vascular health) and laboratory traits (e.g., neutrophil, eosinophil, tau protein, creatinine kinase). Overall, this study finds comprehensive genomic evidence including clinical and regulatory profiles between PTSD, hematologic and cardiometabolic traits, that support comorbidities observed in epidemiologic studies of PTSD.
- 3 March 2022
- Published by Springer Nature in Molecular Psychiatry
- Vol. 27 (3) , 1394-1404
Genetically regulated multi-omics study for symptom clusters of posttraumatic stress disorder highlights pleiotropy with hematologic and cardio-metabolic traits
Posttraumatic stress disorder (PTSD) is a psychiatric disorder that may arise in response to severe traumatic event and is diagnosed based on three main symptom clusters (reexperiencing, avoidance, and hyperarousal) per the Diagnostic Manual of Mental Disorders (version DSM-IV-TR). In this study, we characterized the biological heterogeneity of PTSD symptom clusters by performing a multi-omics investigation integrating genetically regulated gene, splicing, and protein expression in dorsolateral prefrontal cortex tissue within a sample of US veterans enrolled in the Million Veteran Program (N total = 186,689). We identified 30 genes in 19 regions across the three PTSD symptom clusters. We found nine genes to have cell-type specific expression, and over-representation of miRNA-families – miR-148, 30, and 8. Gene-drug target prioritization approach highlighted cyclooxygenase and acetylcholine compounds. Next, we tested molecular-profile based phenome-wide impact of identified genes with respect to 1678 phenotypes derived from the Electronic Health Records of the Vanderbilt University biorepository (N = 70,439). Lastly, we tested for local genetic correlation across PTSD symptom clusters which highlighted metabolic (e.g., obesity, diabetes, vascular health) and laboratory traits (e.g., neutrophil, eosinophil, tau protein, creatinine kinase). Overall, this study finds comprehensive genomic evidence including clinical and regulatory profiles between PTSD, hematologic and cardiometabolic traits, that support comorbidities observed in epidemiologic studies of PTSD.